Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis
| Status: | Recruiting |
|---|---|
| Conditions: | Orthopedic, Metabolic |
| Therapuetic Areas: | Pharmacology / Toxicology, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/2/2016 |
| Start Date: | March 2014 |
Prospective, randomized non-blinded, controlled study to assess the feasibility of the
CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring
renal replacement therapy.
CytoSorb as an adjunct to the standard of care in patients with rhabdomyolysis requiring
renal replacement therapy.
Inclusion Criteria:
- Subject is age 18-80
- Subjects present with rhabdomyolysis
- Subject requires renal replacement therapy and has undergone adequate volume
resuscitation
- Subject is willing to comply with specified follow up requirements
Exclusion Criteria:
- Subject or their legal guardian either declines or cannot give informed consent
- Subject is pregnant
- Subject has been previously enrolled in this clinical study
- Comorbid condition that may limit survival to ≤14 days
- Comorbid condition that could confound study results
- Subjects who are receiving immunosuppressive therapy
We found this trial at
1
site
San Antonio, Texas 78234
Click here to add this to my saved trials
